Evidence map›Paper›PMID 40437310›Full record

ReviewInternational journal of colorectal disease2025

Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.

Yao Xu, Runxiang Xie, Yuqing Weng, Yewei Fang, Shuan Tao, He Zhang, Huimin Chen, Axiang Han, Qi Jiang, Wei Liang

Abstract readReview
In one paragraph

Review in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yao XuDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Runxiang XieDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Yuqing WengHealth Science Center, Ningbo University, Ningbo, China.
Yewei FangDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Shuan TaoDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
He ZhangLaboratory Medical School, Bengbu Medical University, Bengbu, China.
Huimin ChenDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Axiang HanDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Qi JiangDepartment of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo, China. Jiangqigua@163.com.
Wei LiangDepartment of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China. fyyliangwei@nbu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrohn's disease (CD) is a chronic, nonspecific inflammatory bowel disease with a poor prognosis. Despite its increasing incidence, curing CD remains challenging due to its complex etiology and unclear pathogenesis.

methodsA comprehensive PubMed and Web of Science search was conducted using the keywords Crohn's disease, gut microbiota, dysbiosis, pathogenesis and treatment, focusing on studies published between 2014 and 2024.

resultsRecent studies have demonstrated a close relationship between gut microbiota dysbiosis and the development of CD. Although many dysbioses associated with CD have not yet been proven to be causal or consequential, it has been observed that the gut microbiota in CD patients exhibits reduced diversity, a decrease in beneficial bacteria, and an increase in pathogenic bacteria. These changes may lead to decreased intestinal barrier function, abnormal immune responses, and enhanced inflammatory reactions, which are related to the disease's activity, phenotype, drug treatment efficacy, and postoperative therapeutic outcomes. Therefore, further exploration of the microbiota-host interactions and the pathogenesis of CD, the identification of biomarkers, and the development of targeted strategies for modulating the gut microbiota could offer new avenues for the prevention and treatment of CD.

conclusionsThis review highlights the pivotal role of gut microbiota dysbiosis in driving CD pathogenesis and its progression, while underscoring its potential as a therapeutic target through dietary modulation, microbial interventions, and integrative strategies to improve clinical management and prognostic outcomes.

Indexed as

Crohn DiseaseGastrointestinal MicrobiomeHost Microbial InteractionsAnimalsDysbiosisHumansCrohn’s diseaseGut microbial dysbiosisGut microbiotaPathogenesisTreatment

Identifiers

PMID40437310
PMCPMC12119691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.